Hemodynamic effects of continuous urodilatin infusion: a dose-finding study

Area of Science:

• Cardiovascular Physiology
• Renal Physiology
• Pharmacology

Background:

• Urodilatin (ularitide) is a natriuretic peptide with potential hemodynamic effects.
• Understanding its impact on systemic and renal circulation is crucial for therapeutic applications.

Purpose of the Study:

• To evaluate the effects of continuous intravenous urodilatin infusion on systemic and renal hemodynamic parameters in healthy males.
• To determine the safety and efficacy profile of different urodilatin doses.

Main Methods:

• A double-blind, randomized placebo-controlled trial involving 20 healthy males.
• Infusion of urodilatin (7.5, 15, or 22.5 ng/kg/min) or placebo over 300 minutes.
• Noninvasive measurements of cardiac performance and airway function; para-aminohippurate and inulin clearance for renal hemodynamics.

Main Results:

• Urodilatin was tolerated at 7.5 and 15 ng/kg/min; higher doses caused hypotension, nausea, and dizziness.
• 15 ng/kg/min urodilatin significantly increased urine flow (165%), filtration fraction (46%), renal resistance (49%), and systemic vascular resistance (45%).
• Cardiac output decreased across all urodilatin dose groups; renal plasma flow decreased by 31%.

Conclusions:

• Continuous infusion of 7.5 and 15 ng/kg/min urodilatin significantly increases systemic and renal vascular resistance.
• A narrow therapeutic window exists for urodilatin infusion, with doses >20 ng/kg/min posing a high risk for adverse drug reactions.